# NCT02846623 (NCT02846623)

> Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

No report yet. It can be ordered.

- Drugs tested: atezolizumab plus obinutuzumab plus venetoclax
- Indication: chronic lymphocytic leukemia, small lymphocytic lymphoma, Richter syndrome

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02846623
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Chronic Lymphocytic Leukemia; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome; Small Lymphocytic Lymphoma
- Interventions: Atezolizumab; Laboratory Biomarker Analysis; Obinutuzumab; Venetoclax
- Enrollment: 50
- Primary outcome: Minimal residual disease (MRD) negative rate (Cohort I)

## Indexed commentary on NCT02846623 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02846623